Teladoc Health Names Chuck Divita as CEO - Seite 2

Prior to joining GuideWell, Mr. Divita was the Chief Financial Officer of FPIC Insurance Group, a publicly traded P&C insurer primarily focused on the medical professional liability sector. Mr. Divita has previously served on the boards of Prime Therapeutics, Availity, and Vim, among others. He is also focused on community service and has served on the boards of Ronald-McDonald House of Jacksonville and Teach for America, as well as leading the First Coast Heart Ball campaign. Mr. Divita is a Certified Public Accountant and a member of the Florida Institute of Certified Public Accountants (FICPA). 

About Teladoc Health
Teladoc Health empowers all people everywhere to live their healthiest lives by transforming the healthcare experience. As the world leader in whole-person virtual care, Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person’s health journey. Teladoc Health leverages more than two decades of expertise and data-driven insights to meet the growing virtual care needs of consumers and healthcare professionals. For more information, please visit www.teladochealth.com.

Source: Teladoc Health, Inc. – General

NYSE Rule 303A.08 Notice of Inducement Award

Effective June 10, 2024, in connection with commencing employment as Chief Executive Officer, Mr. Divita was granted an award of restricted stock units covering 469,924 shares of Teladoc Health’s common stock, par value $0.001 per share (the “Common Stock”), and an award of performance stock units covering a target of 939,849 shares of Common Stock. The restricted stock units vest, based on continued service to Teladoc Health, as to one-third of the underlying shares on the first anniversary of the grant date, with the remainder vesting quarterly over two years thereafter. The performance stock units provide a target number of shares of Common Stock that would be earned based on (i) Teladoc Health’s adjusted EBITDA for 2025 (“EBITDA PSUs”) and (ii) Teladoc Health’s actual compound annual revenue growth rate during 2025-2027 (“Revenue CAGR PSUs”). Seven-twelfths of any earned EBITDA PSUs would vest on March 10, 2026 and the remaining five-twelfths would vest in five substantially equal quarterly installments over the subsequent 15 months. Any earned Revenue CAGR PSUs would vest on March 1, 2028. The awards were approved by the Compensation Committee of the Board of Directors of Teladoc Health and were granted under the Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan as an employment inducement award pursuant to New York Stock Exchange Rule 303A.08.